Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECOMB: Switch from AZT/lamivudine to Truvada and limb fat redistribution in HIV-1 on HAART
2005-005786-11Phase 4Completed
- Sponsor
- Gilead Sciences
- Start
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of emtricitabine + tenofovir disoproxil in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Gilead Sciences. Primary endpoint: Change in limb fat at Week 48. Started Feb 2006; status: completed.
02
Drugs
emtricitabine + tenofovir disoproxil
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2005-005786-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005786-11.